|
Single arm Phase I/II study of the safety, tolerability and efficacy of the Tocilizumab followed by cisplatin/docetaxel in patients with triple negative locally advanced breast cancer
|
Ongoing
|
TOCILIZUMAB (ACTEMRA)
|
1/2
|
2181156
|
KFSH&RC-R
|
|
Single arm Phase I/II study of the safety, tolerability and efficacy of the investigational anti PD-L1 monoclonal antibody Durvalumab in combination with Paclitaxel in patients with metastatic triple negative PD-L1 positive breast cancer
|
Ongoing
|
Paclitaxel
|
1
|
ESR-14-10649
|
KFSH & RC-R
|
|
Safety and Feasibility of CD19 Chimeric Antigen Receptor (CAR) T Cells In Adults with CD19 Positive Relapsed and Refractory Acute Lymphoblastic Leukemia or Lymphoma
|
Completed
|
CD19-CART
|
1b
|
RC20/446/R
|
NGHA-R
|
|
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
|
Ongoing
|
CARVEDILOL
|
3
|
S1501
|
KFSH & RC-R
|
|
RELATED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH SYMPTOMATIC SICKLE CELL DISEASE: A PROSPECTIVE STUDY
|
Ongoing
|
HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
|
3
|
2191237
|
KFSH&RC-R
|
|
Re-EValuating the Inhibition of Stress Erosions and prophylaxis against gastrointestinal bleeding in the critically ill
|
Ongoing
|
pantoprazole
|
3
|
CT19/009/R
|
King Abdulaziz Medical City NG (Riyadh)
|
|
Re-challenge therapy with chemotherapy and panitumumab in metastatic colorectal cancer patients treated with an anti-EGFR therapy in 1st line treatment: a phase II multicentre study.
|
Ongoing
|
PANITUMUMAB
|
2
|
19-504
|
KAMC
|
|
Randomized, two-way, two- period, single oral dose, open- label, crossover, bioequivalence study to compare Diclofenac Potassium powder for oral solution (50 mg diclofenac potassium) manufactured by Riyadh Pharma versus Catafast® powder for oral solution (50 mg diclofenac potassium) manufactured by Mipharm S.p.A., in healthy subjects under fasting condition.
|
Ongoing
|
DICLOFENAC POTASSIUM
|
1
|
42856
|
Saudi Ajal
|
|
Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia
|
Rejected
|
Dasatinib
|
2
|
LPI-JOR-LEB-KSA-TUN-
|
KFSH & RC - R
|
|
"Randomized, Open Label, Non-inferiority Study of Micafungin Versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients "
|
Completed
|
Micafungin
|
3b
|
9463EC0001
|
NGHA-R
|
